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Abstract
A major issue in organ transplantation is the develop­
ment of a protocol that can preserve organs under 
optimal conditions. Damage to organs is commonly a 
consequence of flow deprivation and oxygen starvation 
following the restoration of blood flow and reoxygenation. 
This is known as ischemia­reperfusion injury (IRI): a 
complex multifactorial process that causes cell damage. 
While the oxygen deprivation due to ischemia depletes 
cell energy, subsequent tissue oxygenation due to 
reperfusion induces many cascades, from reactive oxygen 
species production to apoptosis initiation. Autophagy 
has also been identified in the pathogenesis of IRI, 
although such alterations and their subsequent functional 
significance are controversial. Moreover, proteasome 
activation may be a relevant pathophysiological 
mechanism. Different strategies have been adopted 
to limit IRI damage, including the supplementation of 
commercial preservation media with pharmacological 
agents or additives. In this review, we focus on novel 
strategies related to the ubiquitin proteasome system 
and oxidative stress inhibition, which have been used to 
minimize damage in liver transplantation.
Key words: Liver transplant; Ischemia­reperfusion 
injury; Oxidative stress; Proteasome; Redox regulation; 
Ubiquitin
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Ischemia­reperfusion injury is a complex 
multifactorial process that causes cell damage during 
liver transplantation. The role of the ubiquitin proteasome 
system during liver transplantation remains unclear. The 
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use of proteasome inhibitors is a new strategy aimed at 
improving organ preservation. 
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INTRODUCTION
The definitive treatment option for many liver diseases is 
liver transplantation; and in these cases, one important 
issue is the optimization of organ preservation.
During liver transplantation, damage is initiated by 
vascular occlusion during hepatic resections. This is 
aggravated by cold storage of the liver graft (usually 
at 4 ℃) in the preservation solution; and finally by 
warm reperfusion and subsequent implantation 
into the recipient. During ischemia, a long period of 
tissue hypoxia can result in tissue injury and organ 
dysfunction; as the organ is deprived of oxygen, 
ATP and energy becomes depleted. Paradoxically, 
the reintroduction of oxygen during reperfusion 
aggravates the damage. The whole process has a 
plethora of consequences that are collectively known 
as ischemia-reperfusion injury (IRI)[1-3]. While oxygen 
deprivation due to ischemia depletes cell energy, 
subsequent reoxygenation due to reperfusion induces 
many cascades, from induction of reactive oxygen 
species (ROS)[4] to initiation of apoptosis (Figure 1). 
Such events are, in part, responsible for organ failure. 
Variables related to the donor (age, steatosis) and 
surgery (prolonged ischemia times)[5] are the most 
commonly reported risk factors for graft dysfunction[6]. 
Other factors such as shear stress and small graft size[7] 
have been recognized as important factors associated 
with oxidative stress, lack of primary function, early 
dysfunction allograft and biliary complications after liver 
transplantation[8]. Together with the immunological 
mechanisms of graft rejection, IRI remains as one of the 
main clinical problems following organ transplantation.
Current strategies to prevent and modulate IRI 
include: ischemic pre-[9-15] or post-conditioning[16] 
protocols ; static cold storage[17] or machine perfusion[18-20] 
and the use of pharmacological agents[21-23]. The 
most common methods applied in liver surgery have 
recently been reviewed[5,24]. Conventional hypothermic 
cold storage continues to be the main method for liver 
preservation, largely because of its cost-effectiveness, 
simplicity and logistics. However, hypothermia can have 
multiple side effects, including the induction of oxidative 
stress[25].
Because of the wide range of mechanisms that can 
contribute to cell damage in IRI (involving ROS, oxidized 
products, inflammatory mediators and cytokines), 
adoption of a specific therapeutic strategy often results 
in only limited improvements in organ transplantation. 
Given these circumstances, it is worthwhile to focus 
on the assessment of agents that can counteract the 
damage induced by oxidative stress. As oxidative 
stress is the result of an imbalance between the rate 
of ROS generation and the capacity to detoxify these 
reactive species[26-28], interventions that could result 
in ROS scavenging or the detoxifying of ROS products 
could protect against IRI. Three lines of defence against 
oxidative stress have been reported[29]. Antioxidant 
molecules (such as glutathione) represent the first line 
of antioxidant defence; the second line incorporates 
enzymatic antioxidants; and the third consists of repair 
system proteins, including the proteolytic pathways. In 
this third line, the ubiquitin-proteasome system (UPS) is 
widely recognized as the main system for degradation 
of cytosolic proteins[30,31]
The purpose of this review is to present an update 
of effects of oxidative stress while summarizing recent 
findings on the role of the UPS in organ preservation 
and liver transplantation. In this review we outline 
the current data of the literature, previous search in 
databases - PubMed, Web of Science and Scopus - that 
support the hypothesis on the potential involvement 
of UPS and oxidative stress in IRI. We will focus on 
the new strategies used to minimize damage in liver 
transplantation.
STATIC COLD STORAGE, MACHINE 
PERFUSION AND STORAGE SOLUTIONS
The strategy most commonly adopted to reduce 
ischemic injury is the cooling of organs and the use of 
a preservation solution to minimize enzymatic activity 
and depletion of the energy substrate. Cold storage 
slows down cellular metabolism[32,33], but this can be 
responsible for further ATP and energy depletion[34]. 
In addition, cold has adverse side effects due to the 
induction of cellular inflammation, alterations of the 
cytoskeleton[35] , and oxidative stress. 
Protective strategies to reduce hepatic IRI include 
the use of the machine perfusion, which represents a 
new line of research opposed to static cold storage. 
Perfusion machine involves a pulsatile perfusion of 
the liver with a cold (subnormothermic, hypothermic) 
perfusate[18,36-40]; with normothermic perfusate[41,42]; or 
with a gradual increase in of the perfusate temperature[43]. 
These references confirm that machine perfusion 
protects against IRI damage in animal models. Livers 
preserved by subnormothermic machine perfusion at 
20 ℃ showed significantly less liver damage at the end 
of reperfusion compared to cold storage. The release 
of LDH was reduced while the production of bile, ATP 
levels, glycogen and glutathione content increased in 
preserved livers by subnormothermic machine perfusion 
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than livers submitted to cold storage[44]. Normothermic 
machine perfusion has also been assessed in discarded 
human liver grafts[45]. The reported data demonstrate 
the viability of normothermic perfusion, which results 
in the continuous production of bile, the fall of lactate 
levels and the preservation of hepatic morphology. 
However, the safety and efficacy of machine perfusion 
is yet to be assessed by randomized controlled clinical 
trials. 
Due to its cost-effectiveness and simplicity, cold 
storage with conventional hypothermia remains the 
main method for liver conservation. In fact, major 
advances in the field of organ preservation have 
included the development of new improved preservation 
solutions capable of reducing cold-induced cellular 
damage[46]. Euro-Collins solution was first developed in 
the 1970s; while more recently, University of Wisconsin 
(UW)[47] Celsior[48], Histidine-Ketoglutarate (HTK)[49] 
and Institute Georges Lopez (IGL-1)[50] solutions 
tend to be extensively used for liver transplantation. 
Commercial preservation solutions include oncotic 
agents, like hydroxy-ethyl starch (HES) in UW and 
polyethylenglycol-35 (PEG-35) in IGL-1, which 
confer high viscosity to the media. They also contain 
metabolic precursors (adenosine and ketoglutarate) 
and antioxidants (glutathione, allopurinol). Although the 
use of commercial preservation solutions has improved 
conditions for liver graft preservation, with the urgent 
need to expand the donor pool and the subsequent use 
of suboptimal grafts, new additives have been proposed 
to combat oxidant and apoptotic damage with the aim 
of prolonging graft quality during cold storage.
THE ROLE OF OXIDATIVE STRESS IN IRI
ROS are highly reactive and capable of oxidizing lipids, 
proteins and DNA[51], thereby leading to structural and 
cellular changes that may cause oxidative stress and 
cellular apoptosis. Abundant information has been 
published demonstrating that increased ROS production 
is involved in IRI pathology[28,50,52,53]. The involvement 
of ROS was initially observed based on the detection of 
enhanced production of chemical products generated 
by the reaction of ROS with cellular components. Lipid 
peroxidation products, such as malondialdehyde and 
hydroxynonenal[13,36,54-56] have been widely used as a 
biomarkers of oxidative stress in IRI. The accelerated 
ROS production in post-ischemic tissues has been 
attributed to enzymes capable of reducing molecular 
oxygen and forming superoxide: xantine oxidase[57-59], 
NADPH oxidase[60] and nitric oxide synthase[11]. The 
contribution of each of these enzymes in IRI is assessed 
in the excellent review by Granger and Kvietys[28]. All 
this indicates that radicals can be formed from different 
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Figure 1  Ischemia-reperfusion injury: A complex multifactorial process that causes cell damage during liver transplantation. While the oxygen deprivation 
due to ischemia depletes cell energy, subsequent reoxygenation due to reperfusion induces many cascades, from production of reactive oxygen species to initiation of 
apoptosis. UPS: Ubiquitin-proteasome system; mPTP: mitochondrial permeability transition pore.
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activated ubiquitin moieties to the protein substrate 
that is specifically bound to a unique ubiquitin ligase: 
E3. Finally, an isopeptide bond is formed between the 
C-terminal glycine residue of the ubiquitin (Gly76) and 
the e-NH2 group of an internal lysine (Lys119) of the 
protein substrate. Several protein families have been 
discovered that are evolutionarily related to ubiquitin, 
as they share the characteristics of the ubiquitin-fold 
proteins and the capacity to become conjugated to 
substrates through the action of related E1, E2, and E3 
enzymes[79].
Target proteins can be modified by mono- or poly-
ubiquitination. The seven lysines in ubiquitin contribute 
to the assembly of various poly-ubiquitin chains that 
may be involved in different cellular processes[80]. 
The K48-linked (Lys 48) poly-ubiquitin chain targets 
proteins for proteasomal degradation, while the K11-
linked poly-ubiquitin chain is involved in endoplasmic 
reticulum-associated degradation[81] and the K63-
linked poly-ubiquitin chain can act in non-proteolytic 
events, including protein trafficking, DNA repair, and 
inflammation[82]. Furthermore, ubiquitination can be 
reversed by the removal of ubiquitin from target proteins 
by de-ubiquitinating enzymes (DUBs).
Degradation of damaged proteins
The proteasome is a multicatalytic protease involved in 
the degradation of intracellular proteins. The processing 
of damaged proteins is mainly mediated by the 20S and 
26S proteasomes[76,77]. 
The 20S proteasome is a large complex, formed of 
four stacked rings: two alpha and two beta rings, each 
containing seven different subunits (from α1 to α7 or 
from β1 to β7). Three of the beta subunits are responsible 
for the proteolytic activity. β1 exhibits caspase-like 
activity, while β2 exhibits trypsin-like activity, and β5, 
chymotrypsin-like activity. Whereas the beta rings are 
responsible for proteolytic degradation, the alpha rings 
perform substrate recognition and regulate substrate 
access to the proteolytic active centre. 
The 26S proteasome is formed by the addition of 
one or two regulatory 19S subunits to an alpha ring 
in the 20S core proteasome in an ATP-dependent 
manner. The binding to this regulator increases the 
proteasomal activity and allows the proteasome to 
degrade the substrate proteins that have been tagged 
through the binding of a chain of ubiquitin, as explained 
above. The ubiquitin chain acts as a labelled sequence 
to direct proteins to the 26S proteasome where they 
are degraded. The 19S subunits first remove the 
poly-ubiquitin “tags” of the targeted proteins and 
unfold those proteins. Then, the unfolded proteins are 
degraded by the 20S core of the 26S proteasome. In 
this way, while the 20S core proteasome can degrade 
unfolded proteins in an ATP-independent manner, the 
26S proteasome is only capable of degrading natively 
folded and functional proteins in an ATP- and ubiquitin-
sources, and consequently several protective strategies 
to decrease liver IRI have targeted different sources 
of ROS: xanthine oxidase (using allopurinol[59,61]) or 
NADPH oxidase[62], for example. Other strategies have 
included pharmacological interventions with antioxidants 
resulting in the neutralization of ROS effects[63-66]. 
As mentioned above, Jung et al[29] describe three 
main lines of defence against oxidative stress. Thus, 
to those molecules widely recognized as antioxidants, 
such as glutathione, and enzymatic antioxidants, they 
add a third line of defence: repair system proteins. This 
system includes the proteolytic pathways, such as the 
UPS[30,31]. The activity of the UPS is necessary so that 
the cells can cope with oxidative stress, but in turn, the 
activity of the UPS are also modulated by the redox 
state[67].
THE UBIQUITIN-PROTEASOME SYSTEM
In order to eliminate damaged proteins, cells have 
highly regulated mechanisms, such as the autophagy-
lysosome pathway and the UPS, which is recognized 
as the principal system for degrading oxidized cytosolic 
proteins. Proteasomes are protein complexes that, via 
proteolysis, degrade unnecessary or damaged proteins. 
It has always appeared that autophagy within lysosomes 
is involved in the pathogenesis of hepatic IRI, although 
the specific alterations it causes and their subsequent 
functional significance are highly controversial[68]. The 
use of proteasome inhibitors has been demonstrated 
to enhance myocardial viability[69,70] and protect liver 
against IRI[4,71-73], which suggests this may be a 
promising strategy to reduce the damage inherent to 
transplantation protocols. 
Ubiquitin 
Ubiquitin is a highly conserved and small 76-amino-
acid protein that acts as a post-translational protein 
modifier and regulates protein lifespan. Ubiquitin was 
isolated in the 1970s by Goldstein et al[74] and since 
then has been identified in many cellular processes, 
including proteasomal proteolysis and also DNA damage 
repair. Ubiquitin can be attached covalently to a target 
protein in a process known as ubiquitination. Ubiquitin 
is conjugated to other proteins through a peptide 
bond between its C-terminal glycine and a primary 
amine on the substrate, most typically a lysine residue. 
Conjugation is dependent on the successive activities 
of enzymes named E1 (ubiquitin activating enzyme), 
E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin 
ligase)[75]. In the 1980s, biochemical studies elucidated 
the chemical reactions catalysed by these enzymes[76,77]. 
E1 activates ubiquitin as a thioester of the active site 
cysteine residue at expenses of ATP[78]. The activated 
ubiquitin molecule is then transferred to an E2 enzyme 
via the formation of a new thioester with the catalytic 
cysteine residue of the E2 enzyme. E2 transfers the 
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dependent manner[83]. 
ACTIVATION OF THE PROTEASOME 
UBIQUITIN SYSTEM (UPS) AND 
PROTEOLYSIS IN IRI
It has been well established that proteolysis is an 
important regulatory mechanism that helps maintain 
homeostasis[77]. The proteasome and the UPS are 
necessary for the control of protein concentrations, 
to prevent abnormal accumulations and to modulate 
regulatory proteins involved in cell metabolism. 
However, proteolysis can have detrimental effects on 
organs and tissues after transplantation[84]. Free amino 
acids in the effluent from human livers was used as a 
marker to predict postoperative graft function. In fact, 
the prevention of liver graft proteolysis and proteasome 
activation can be modulated by the use of additives to 
organ preservation solutions[85,86]. In this way, it has 
been demonstrated that lactobionate, a component of 
UW solution, prevents the release of metalloproteinases 
during cold preservation[85]. Moreover, the UPS is an 
energy-dependent system and ATP levels affects 26S 
proteasome assembly, stability, and function[87]. The 
following processes are dependent on ATP: The first 
step in ubiquitin conjugation by E1, which is required 
for the poly-ubiquitination of proteins; the assembly of 
alpha and beta rings and ATP-dependent proteases; 
and the degradation of poly-ubiquinated proteins by the 
26S proteasome[79,87]. In addition, it is well known that 
oxygen deprivation leads to a significant decrease in 
ATP in liver grafts[34], which could affect liver outcomes. 
Therefore, during cold storage of organs, and because 
of the ATP decrease, the formation of 26S proteasomes 
and poly-ubiquitin-dependent protein degradation are 
expected to be impaired. However, it has been well 
established that a subset of 26S proteasomes appears 
to be activated as ATP levels decline[70]. In that study, 
Geng et al[70] demonstrated that the activation of the 26S 
proteasome is a pathophysiologically relevant mechanism 
in cold ischemic myocardial injury. Such observations 
imply that a subset of 26S is acting as a harmful 
protease that is activated when the cellular energy supply 
decreases. The finding that ATP negatively regulates 
proteasome activity is consistent with previous results 
concerning increased proteolysis during cold preservation 
of human liver grafts[84]. Moreover, hypothermia also 
affects proteasome activity in isolated perfused rat liver, 
increasing chymotrypsin-like activity[36].
Degradation of protein substrates by 26S prote-
asomes requires the 19S regulatory cap to recognize 
ubiquitin protein conjugates and to regulate the entry of 
the substrate into the proteolytic cavity of the 20S core. 
Covalent regulation via phosphorylation of a subunit in 
the 19S regulatory cap of the proteasome allows for 
a fast increase in the 26S proteasome activity, which 
becomes an important regulatory mechanism for 
proteasome control[88-90]. In fact, we have previously 
reported that phosphorylation of the 19S subunit Rpt6 
increases in cold perfused rat livers[36].
The combination of proteasome and oxidative stress in 
IRI
ROS are capable of oxidatively modifying cell structures. 
Due to the abundance of proteins, the presence 
of oxidatively modified proteins and aggregates of 
oxidized proteins has been reported in the cytosol. 
There is a certain degree of consensus that proteasomal 
activity degrades oxidized proteins, although the 
attribution to 20S or 26S is yet to be elucidated. The 
26S proteasome was found to be less active in the 
degradation of oxidatively damaged proteins[91]. A 
growing body of evidence suggests that the degradation 
of oxidatively damaged proteins does not require ATP 
and polyubiquitination of the substrate[92]. Alternatively, 
oxidative proteins are removed independently of 
ubiquitin by the ATP-independent 20S proteasome[93]. 
The proteasome is responsible for the selective 
degradation of oxidatively damaged proteins. In this 
sense it has been shown that certain oxidized proteins 
degrade faster than their native counterparts[94], and, 
furthermore, it has been shown that inhibition of the 
proteasome stabilizes the oxidized proteins[95]. During 
oxidative stress, the ratio of oxidized to reduced 
glutathione increases[36]. and this redox status of 
the cells can also modulate protein ubiquitination by 
reversible S-thiolation[96,67]. This is concurrent with 
a decrease in the ubiquitin-activating enzyme, E-1 
and ubiquitin conjugates. According to some models, 
glutathiolation of the E1 or E2 components of a ubi-
quitinated protein protects it from unnecessary degra-
dation. Thus, S-glutathiolation can be regarded as a 
general mechanism of a redox signal controlling gene 
expression. In addition, direct oxidative modifications of 
the proteasome may also occur, including carbonylation, 
glycoxidation and modification with lipid peroxidation 
products. Although it is not clear to what extent these 
modifications affect the proteasome, they could 
modulate proteasomal activity. It should be noted that 
an inefficient proteasomal system would result in an 
accumulation of protein aggregates in the cytoplasm, as 
has been reported in brain due to aging or Alzheimer’s 
disease[97]; while excessive protein depletion activity may 
have deleterious effects by affecting detoxifying systems, 
membranes, or RNA stability[69,84]. 
PROTEASOME INHIBITION IN LIVER IRI
The use of proteasome inhibitors has been shown to 
offer protection and maintain the physiological ubiquitin-
protein conjugate pool during cold organ preservation[98]. 
Table 1 summarizes the protective effects of different 
proteasome inhibitors against IRI during organ preser-
vation. The potential pharmacological role of proteasome 
inhibitors was first reported by Campbell et al[99]. Those 
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authors demonstrated that proteasome inhibition can 
prevent loss of cardiac contractile function in isolated 
perfused rat heart. The adherence of polymorphonuclear 
leukocytes to the endothelium was also reduced. 
However, controversy regarding whether inhibiting the 
proteasome is beneficial or detrimental to cardiac function 
continues[95]. Few studies have examined the role of UPS 
inhibitors as a strategy to reduce damage in liver IRI. In 
rat liver subjected to warm IRI, the administration of the 
proteasome inhibitor MG132 decreased LDH and AST 
levels during ischemia and reperfusion[4]. In addition, the 
same authors studied whether MG132 can modulate the 
prooxidant and antioxidant status of rat liver. The results 
showed that MG132 did not significantly affect liver 
lipid peroxidation. However, MG132 increased protein 
carbonyls and decreased the main antioxidant enzyme 
activities (catalase and superoxide dismutase).
In contrast to that modulation of oxidative stress, the 
proteasome inhibitor Bortezomib, used at a non-toxic 
low dose, up-regulates liver antioxidant enzymes in 
chronic ethanol-fed rats[86]. Exposure to the proteasome 
inhibitor increased antioxidant defences by enhancing 
the levels of mRNA and protein expression transcripts 
of glutathione reductase, glutathione synthetase and 
glutathione peroxidase, as well as superoxide dismutase 
in rat liver. The increase in antioxidant defences was 
concomitant with enhanced 26S proteasome activity. 
As mentioned by those authors, the beneficial effects 
of the proteasome inhibitor Bortezomib could be due to 
the low dose used and to the reversibility of the drug. 
In accordance with the previous research, we have 
recently demonstrated that the addition of the reversible 
UPS inhibitors Bortezomib and MG132 to UW solution 
improved steatotic and non-steatotic rat liver preservation 
in the face of cold IRI[71]. Both inhibitors prevented liver 
injury, decreasing AST and ALT, and prevented the 
release of the inflammatory cytokines IL-1 beta and TNF-
alpha. The protective effect of Bortezomib was superior 
to that of MG132. Bortezomib increased bile production, 
decreased vascular resistance in fatty rat liver through 
an increase in nitric oxide generation, prevented lipid 
peroxidation and mitochondrial damage, and increased 
AMP-activated protein kinase (AMPK) phosphorylation. 
It is well known that AMPK phosphorylation is a key 
process in fatty liver graft preservation, as it can reduce 
inflammation[9,44].
The supplementation of IGL-1 preservation solution 
with Bortezomib has also been shown to have protective 
effects[72], reducing steatotic liver injury and decreasing 
liver apoptosis (cytochrome c and caspase 3 release) 
in the face of cold IRI. These effects were partially 
mediated through the activation of the Akt/mTOR 
signalling pathway, a key regulator in cell growth and 
proliferation, and through the phosphorylation of AMPK.
Besides its role in preventing inflammation, AMPK 
activation also keeps the liver in an energy-conserving 
state during cold storage. AMPK triggers ATP-producing 
pathways, balancing the metabolic process towards 
increasing energy homeostasis in the cell. We have 
recently found a correlation between AMPK activation, 
ATP levels, lower proteasome activity and decreased 
damage in fatty liver grafts preserved in different 
solutions[73]. As AMPK is regulated and degraded by the 
UPS, the use of proteasome inhibitors in the preservation 
solution could avoid AMPK depletion and may contribute 
to maintaining the beneficial effects of proteasome 
inhibition after IRI. 
CONCLUSION
Remarkable progress has been made over the past 
few decades regarding the role of the UPS in many 
cellular processes. However, the function and regulation 
of the proteasome in organ transplantation still 
remains unclear. We have proposed that UPS inhibitors 
reduce IRI in liver grafts via up-regulation of AMPK 
phosphorylation and the consequent preservation of 
the energy state. As some proteasome inhibitors have 
been approved for the treatment of different diseases, 
we propose to explore their use in liver. Well-designed 
Table 1  Effect of different proteasome inhibitors on organ preservation 
Inhibitor Organ and condition Manifestations Ref.
PS-519 Heart after IRI (rat) Improved cardiac contractility Campbell et al[99]
Improved coronary flow
Reduced PMN infiltration
Epoxomicin Heart after cold ischemia (rat) Reduced edema formation Geng et al[70]
Preserved ultrastructural integrity
MG132 Liver, warm IRI (rat) Decreased LDH and ALT Alexandrova et al[4]
Increased protein oxidation 
Decreased antioxidant activities
MG132 Liver, cold IRI (rat) Decreased AST and ALT Zaouali et al[71]
Reduced inflammation (IL1β and TNFα)
Bortezomid Liver, cold IRI (rat) Decreased AST, ALT and mitochondrial damage Zaouali et al[71]
Increased bile production Bejaoui et al[72]
Decreased lipid peroxidation
Decreased apoptosis (Cyt C and Caspase 3)
IRI: Ischemia-reperfusion injury.
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randomized controlled trials will be needed to evaluate 
the use of proteasome inhibitors in liver transplantation. 
The supplementation of low and non-toxic doses of 
proteasome inhibitors offers a new opportunity for the 
improvement of organ preservation solutions.
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